American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma.
about
A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignanciesBisphosphonates: mechanism of action and role in clinical practiceProblems monitoring response in multiple myelomaMedication-related osteonecrosis of the jaw: Clinical and practical guidelinesJaw bone necrosis without previous dental extractions associated with the use of bisphosphonates (pamidronate and zoledronate): a four-case reportUse of Ultrasonic Bone Surgery (Piezosurgery) to Surgically Treat Bisphosphonate-Related Osteonecrosis of the Jaws (BRONJ). A Case Series Report with at Least 1 Year of Follow-Up.Efficacy and tolerability of medical ozone gas insufflations in patients with osteonecrosis of the jaw treated with bisphosphonates-Preliminary data: Medical ozone gas insufflation in treating ONJ lesionsStatins Are Associated With Reduced Mortality in Multiple Myeloma.Risk factors for osteonecrosis of the jaws: a case-control study from the CONDOR dental PBRNRisk Assessment of BRONJ in Oncologic Patients Treated with Bisphosphonates: Follow-Up to 18 MonthsDenosumab in patients with cancer and skeletal metastases: a systematic review and meta-analysis.Osteoclast targeted therapy for prostate cancer: bisphosphonates and beyond.Zoledronic Acid may reduce intraoperative bleeding in spinal tumors: a prospective cohort studyCell-based immunotherapy with mesenchymal stem cells cures bisphosphonate-related osteonecrosis of the jaw-like disease in mice.Novel therapeutic approaches for multiple myeloma.RANK/RANKL/OPG signaling pathways in necrotic jaw bone from bisphosphonate-treated subjectsOptimizing clinical benefits of bisphosphonates in cancer patients with bone metastases.Quality of life implications of bisphosphonate-associated osteonecrosis of the jaw.How concerns for bisphosphonate-induced osteonecrosis of the jaw affect clinical practice among dentists: a study from the South Texas Oral Health Network.New insights into the pathophysiology and management of bone disease in multiple myeloma.Bisphosphonate therapy in the oncology setting.Bisphosphonate-associated osteonecrosis of the jaw: the rheumatologist's role.Effect of the cumulative dose of zoledronic acid on the pathogenesis of osteonecrosis of the jaws.Time associated with intravenous zoledronic acid administration in patients with breast or prostate cancer and bone metastasisPharmaceutical inhibition of glycogen synthetase kinase-3β reduces multiple myeloma-induced bone disease in a novel murine plasmacytoma xenograft modelBisphosphonate therapy in multiple myeloma in preventing vertebral collapses: preliminary report.Targeting cells of the myeloid lineage attenuates pain and disease progression in a prostate model of bone cancerMyeloma bone disease: pathophysiology and management.Bisphosphonate induced osteonecrosis of jaw in breast cancer patients: A systematic reviewCurrent therapeutic uses of lenalidomide in multiple myeloma.Common complaints, difficult diagnosis: multiple myeloma.Oral care and the use of bone-targeted agents in patients with metastatic cancers: A practical guide for dental surgeons and oncologists.A systematic review of dosing frequency with bone-targeted agents for patients with bone metastases from breast cancer.Acute kidney injury and bisphosphonate use in cancer: a report from the research on adverse drug events and reports (RADAR) projectDecreasing frequency of osteonecrosis of the jaw in cancer and myeloma patients treated with bisphosphonates: the experience of the oncology network of piedmont and aosta valley (north-Western Italy)Zoledronic acid in the management of metastatic bone disease.Bisphosphonate-induced osteonecrosis of the jaw.Associations between Systemic Markers of Bone Turnover or Bone Mineral Density and Anti-Resorptive Agent-Related Osteonecrosis of the Jaw in Patients Treated with Anti-Resorptive Agents.Bisphosphonate-associated osteonecrosis of the jawThe safety of zoledronic acid.
P2860
Q21245492-2F7B5264-41D4-42EC-B3DC-AFC863537800Q24644708-F73C9A04-FB1B-496B-80DC-AE238F57EA9AQ24676888-F3E1D005-C91A-4972-9796-BD919FE5EE2FQ26749965-75127DB3-CEDE-449A-8F2D-0C09BF80843DQ28275303-FF43E9C6-B50B-4938-8AF7-5B61B2332E51Q30449286-772CD42A-D81E-4354-96EB-981727C5EF60Q31048683-741EF60E-B990-4D43-82A9-3E6DFE89A958Q33816591-A0D2A860-E81E-4342-8A9B-704EF87D4370Q34164223-D8355D3E-60B0-4811-99AC-F1EB3E393D09Q34204571-AB94CF3B-15E1-4070-8393-639646BB8939Q34381979-F243BB7F-A012-45DF-AE6F-470A67C0E102Q34960635-C8480755-D200-4926-BB26-05460E76C8A1Q35050733-79CF69B1-E496-4DEB-94FD-DC9A746CB210Q35157851-64989AFE-8C09-443F-B082-C52776415624Q35170935-187AE987-09F3-449B-A655-BB6CA7CB94B8Q35228787-826CFDF4-9733-45FB-8B16-FE60F870AFC5Q35583788-018A8D2D-1A87-4B4C-8A03-493ED12293F7Q35584343-56A1FE09-AE15-48FD-85B2-95A66F5EA521Q35590055-A3DF1FF7-5039-4535-896F-17D9504D5647Q35591086-EF7AAED7-98ED-4AEE-B8CD-6BFB0BC198E5Q35602668-0EF9F4C9-01E0-45A3-ACE0-247294D72A5BQ35605709-6A19BF16-09D2-4E97-971E-C3A5ACA5212EQ35803713-D5DFB739-9644-4952-BFD8-2CC04301E496Q35832155-E4185C6E-E100-4159-A9C9-A4AD1B99FA51Q35868347-9F141B67-00D4-49FA-A639-86E7C6518F8DQ35886257-59625675-9511-4C13-A483-8AFA34575467Q35985440-247F17C6-7714-484A-97C2-23BB196A366EQ36146493-0F4C5CCD-BD31-4F47-9A9C-46F138683F65Q36181162-D9410521-A079-441A-89EA-60747CC02756Q36376450-2F66D056-F7B1-48CC-9B99-FD90834A9E25Q36471721-BA7EB51B-69A1-4992-B2F3-8574D2610ADCQ36491413-C2D2E5DE-B716-4A4C-81EF-FD19FEF3FD19Q36491537-56D9F282-010C-4A06-B000-06F62D0A8FB5Q36678173-B37159CC-DCAA-4367-A222-43B49D25624AQ36691952-4C970661-DEDF-4D34-AD9E-F2745DD76E35Q36708315-B5BBD1A7-6ECE-4288-A8AE-59A8BFB3DA80Q36735192-C1507331-65D9-49F2-A6DB-E1AA4C705536Q36753894-C32D53CB-DBB2-452A-A7D8-A7F0E26C6536Q36767037-DB7ACFD7-EE09-4C84-A4E9-BC1C0C885205Q36811542-9E216633-8119-4D3D-A3D8-12E68CA32FD8
P2860
American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma.
description
2002 nî lūn-bûn
@nan
2002 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
American Society of Clinical O ...... sphonates in multiple myeloma.
@ast
American Society of Clinical O ...... sphonates in multiple myeloma.
@en
American Society of Clinical O ...... sphonates in multiple myeloma.
@nl
type
label
American Society of Clinical O ...... sphonates in multiple myeloma.
@ast
American Society of Clinical O ...... sphonates in multiple myeloma.
@en
American Society of Clinical O ...... sphonates in multiple myeloma.
@nl
prefLabel
American Society of Clinical O ...... sphonates in multiple myeloma.
@ast
American Society of Clinical O ...... sphonates in multiple myeloma.
@en
American Society of Clinical O ...... sphonates in multiple myeloma.
@nl
P2093
P356
P1476
American Society of Clinical O ...... sphonates in multiple myeloma.
@en
P2093
Allan Lipton
American Society of Clinical Oncology Bisphosphonates Expert Panel
Bruce E Hillner
Gary C Yee
J Sybil Biermann
James R Berenson
Ken Anderson
P304
P356
10.1200/JCO.2002.06.037
P407
P577
2002-09-01T00:00:00Z